Malignant tumours secrete factors that enable them to commandeer their own blood supply (angiogenesis), and blocking the action of these factors can inhibit tumour growth. But because tumours may become resistant to treatments that target individual angiogenic factors by switching over to other angiogenic molecules1,2, a cocktail of multiple anti-angiogenic agents should be more effective. Here we show that herceptin3, a monoclonal antibody against the cell-surface receptor HER2 (for human epidermal growth factor receptor-2; ref. 4), induces normalization and regression of the vasculature in an experimental human breast tumour that overexpresses HER2 in mice, and that it works by modulating the effects of different pro- and anti-angiogenic factors. As a single agent that acts against multiple targets, herceptin, or drugs like it, may offer a simple alternative to combination anti-angiogenic treatments.
Subscribe to Journal
Get full journal access for 1 year
only $3.83 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Jain, R. K. & Carmeliet, P. F. Sci. Am. 285, 38–45 (2001).
Fidler, I. J. J. Natl Cancer Inst. 93, 1040–1041 (2001).
Slamon, D. J. et al. N. Engl. J. Med. 344, 783–792 (2001).
Yarden, Y. & Sliwkowski, M. X. Nature Rev. Mol. Cell Biol. 2, 127–137 (2001).
Kerbel, R. S., Viloria-Petit, A., Klement, G. & Rak, J. Eur. J. Cancer 36, 1248–1257 (2000).
Allgayer, H. et al. J. Clin. Oncol. 18, 2201–2209 (2000).
Nicolini, G., Miloso, M., Moroni, M. C., Beguinot, L. & Scotto, L. J. Biol. Chem. 271, 30290–30296 (1996).
Thurston, G. et al. Science 286, 2511–2514 (1999).
Bornstein, P. J. Clin. Invest. 107, 929–934 (2001).
Jain, R. K. Nature Med. 7, 987–989 (2001).
Fukumura, D. et al. Cell 94, 715–725 (1998).
Jain, R. K., Munn, L. L. & Fukumura, D. Nature Rev. Cancer (in the press).
The study reported in this paper was in part supported by Genentech.
brief communications is intended to provide a forum for both brief, topical reports of general scientific interest and technical discussion of recently published material of particular interest to non-specialist readers. Priority will be given to contributions that have fewer than 500 words, 10 references and only one figure. Detailed guidelines are available on Nature's website (http://www.nature.com) or on request from firstname.lastname@example.org
About this article
Cite this article
Izumi, Y., Xu, L., di Tomaso, E. et al. Herceptin acts as an anti-angiogenic cocktail. Nature 416, 279–280 (2002). https://doi.org/10.1038/416279b
A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action
Molecular Immunology (2020)
Dual pH- and GSH-Responsive Degradable PEGylated Graphene Quantum Dot-Based Nanoparticles for Enhanced HER2-Positive Breast Cancer Therapy
Metastatic Breast Cancer Patient With Activating HER2 Exon 20 Insertion Mutation With Response to Poziotinib: Case Report of Compassionate Drug Use
Clinical Breast Cancer (2019)
Nature Reviews Cancer (2019)
Current Pharmaceutical Design (2019)